

# Julie George

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4441297/publications.pdf>

Version: 2024-02-01

20  
papers

4,629  
citations

430874

18  
h-index

752698

20  
g-index

21  
all docs

21  
docs citations

21  
times ranked

7090  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive genomic profiles of small cell lung cancer. <i>Nature</i> , 2015, 524, 47-53.	27.8	1,634
2	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. <i>Nature Genetics</i> , 2012, 44, 1104-1110.	21.4	1,186
3	MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. <i>Cancer Cell</i> , 2017, 31, 270-285.	16.8	406
4	Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. <i>Nature Communications</i> , 2018, 9, 1048.	12.8	254
5	Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. <i>Nature Communications</i> , 2014, 5, 3518.	12.8	239
6	Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. <i>Cancer Discovery</i> , 2018, 8, 600-615.	9.4	157
7	New Approaches to SCLC Therapy: From the Laboratory to the Clinic. <i>Journal of Thoracic Oncology</i> , 2020, 15, 520-540.	1.1	119
8	PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations. <i>Oncotmmunology</i> , 2016, 5, e1131379.	4.6	94
9	Genomic Amplification of <i>CD274</i> (PD-L1) in Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1220-1226.	7.0	92
10	<i>ATM</i> Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma. <i>Cancer Research</i> , 2017, 77, 3040-3056.	0.9	81
11	Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer. <i>Cell Reports</i> , 2016, 16, 644-656.	6.4	73
12	Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes. <i>Nature Communications</i> , 2021, 12, 2048.	12.8	66
13	Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer. <i>Scientific Reports</i> , 2017, 7, 15511.	3.3	54
14	Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. <i>Genome Biology</i> , 2015, 16, 7.	8.8	44
15	Mechanisms of Primary Drug Resistance in <i>FGFR1</i> -Amplified Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5527-5536.	7.0	44
16	MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I. <i>Nature Communications</i> , 2021, 12, 5505.	12.8	30
17	Depletion of histone methyltransferase KMT9 inhibits lung cancer cell proliferation by inducing non-apoptotic cell death. <i>Cancer Cell International</i> , 2020, 20, 52.	4.1	25
18	Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. <i>Nature Communications</i> , 2021, 12, 6655.	12.8	24

#	ARTICLE	IF	CITATIONS
19	BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for responseâ€”Preliminary results from the SCLC cohort.. Journal of Clinical Oncology, 2019, 37, 8563-8563.	1.6	4
20	BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for responseâ€”Preliminary results from the NSCLC cohort.. Journal of Clinical Oncology, 2019, 37, e20550-e20550.	1.6	3